This is a registry record, not a result. A trial being listed, recruiting or completed says nothing by itself about whether the compound works or is safe.
| Registry number | NCT06066515 |
|---|---|
| Status | Completed |
| Phase | Phase 3 |
| Sponsor | Boehringer Ingelheim |
| Enrollment | 726 participants |
| Design | Interventional, Randomized, Parallel, Masking: Quadruple |
| Conditions | Obesity |
| Interventions | survodutide; Placebo |
| Start | Nov 25, 2023 |
| Primary completion | Dec 2, 2025 |
| Study completion | Feb 20, 2026 |
| Results posted | Not yet |
| Registry last updated | Mar 12, 2026 |
Compounds on this site that cite this trial
What the registry says the trial is about
This study is open to adults who are at least 18 years old and have
* a body mass index (BMI) of 30 kg/m² or more, or
* a BMI of 27 kg/m² or more and at least one health problem related to their weight.
People with type 2 diabetes cannot take part in this study. Only people who have previously not managed to lose weight by changing their diet can participate.
The purpose of this study is to find out whether a medicine called survodutide (BI 456906) helps people living with overweight or obesity to lose weight. Participants are divided into 3 groups by chance, like drawing names from a hat. 2 groups get different doses of survodutide and 1 group gets placebo. Placebo looks like survodutide but does not contain any medicine. Every participant has a 2 in 3 chance of getting survodutide. Participants inject survodutide or placebo under their skin once a week for about one and a half years. In addition to the study medicine, all participants receive counselling to make changes to their diet and to exercise regularly.
Participants are in the study for about 1 year and 7 months. During this time, it is planned that participants visit the study site up to 14 times and receive 6 phone calls by the site staff.
The doctors check participants' health and take note of any unwanted effects. The participants' body weight is regularly measured. The results are compared between the groups to see whether the treatment works.
Primary outcomes
These are what the trial was designed to measure first. They are registered in advance, which is what makes a later result checkable.
| Outcome measure | Time frame |
|---|---|
| Percentage change in body weight from baseline to Week 76 | Baseline and at Week 76 |
| Achievement of body weight reduction u22655% (yes/no) from baseline to Week 76 | Baseline and at Week 76 |
31 secondary outcomes also registered. See the registry record for the full list.
Source: ClinicalTrials.gov (U.S. National Library of Medicine). Last checked against the registry on Oct 3, 2026. See the trial changes feed for what has changed recently.
